Holen Sie sich die Stockscreener-App
1.06
0.00%
0.00
Schlusskurs vom Vortag:
$1.06
Offen:
$1.06
24-Stunden-Volumen:
257.40K
Relative Volume:
0.39
Marktkapitalisierung:
$122.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.33M
KGV:
-3.7535
EPS:
-0.2824
Netto-Cashflow:
$-17.65M
1W Leistung:
-0.93%
1M Leistung:
-17.19%
6M Leistung:
+4.95%
1J Leistung:
-19.70%
1-Tages-Spanne:
$1.045
$1.08
1-Wochen-Bereich:
$1.02
$1.10
52-Wochen-Spanne:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.06 | 122.19M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiol Therapeutics Inc (CRDL) Institutional Confidence - TradingKey
Cardiol Therapeutics Inc (CRDL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiol Therapeutics Inc (CRDL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
Moderna to Host Investor EventScience Day - Investing News Network
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiol Therapeutics Inc (CRDL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRDL Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineConsensus Miss Rate - newsline.com
Cardiol Therapeutics (CRDL) Dips 4.7% as Shares Test Key Support LevelsWave Truncation - The Legal Advocate
Cardiol Therapeutics (CRDL) Sees Minor Decline, Holds Above Key SupportHull Moving Average - newsline.com
Cardiol Therapeutics Sets June 24, 2026 Virtual AGM and Adopts Notice-and-Access for Proxy Materials - TipRanks
Cardiol Therapeutics (Nasdaq: CRDL) outlines 2026 virtual shareholder meeting - Stock Titan
Cardiol Therapeutics Inc. (CRDL) Modestly Advances as It Holds Above Key SupportStop Hunt - The Legal Advocate
CRDL Q4 2025 Earnings: Narrower Loss Surpasses Estimates Amid Clinical ProgressSurprise Factor Analysis - newsline.com
CRDL Q4 2025 Earnings: Loss Narrows as EPS Beats Estimates by 14.2%Financial Data - newsline.com
CRDL Q4 2025 Earnings: Narrower Than Expected Loss as Cardiol Therapeutics Advances Clinical PipelineEPS Revision Trend - newsline.com
CRDL Stock Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
Cardiol Therapeutics Inc (TSX:CRDL) Stock Price & 30 Year Financial Data - GuruFocus
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CRDL News | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily
[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - Yahoo Finance
Cardiol Therapeutics Inc.Class A Common Shares (NQ: CRDL - FinancialContent
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
TradingKey - TradingKey
Cardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQ - TipRanks
Cardiol Therapeutics (CRDL) joins H.C. Wainwright BioConnect investor Fireside Chat at NASDAQ - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - The Globe and Mail
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position - TipRanks
Cardiol Therapeutics (CRDL) extends cash runway and advances late-stage heart trials - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion - TipRanks
Phase II MAvERIC data for CardiolRx in pericarditis to appear in JAHA for Cardiol (NASDAQ: CRDL) - Stock Titan
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PR Newswire
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Phase III Trial Enrollment Reached (75%) for Promising - openPR.com
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):